Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Obodence 60 mg solution for injection in pre-filled syringe
Medicines register · Ireland

Obodence 60 mg solution for injection in pre-filled syringe

Authorisation EU/1/24/1890/001 · Samsung Bioepis NL B.V.

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 22 Nov 2026
Licence holder
Samsung Bioepis NL B.V. (all products →)
Active substance
Denosumab
Clinical trials
24 clinical trials →
Dosage form
Solution for injection in pre-filled syringe
Route of administration
Subcutaneous use
ATC code
M05BX04
First authorised
12/02/2025
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Similar biological application (Article 10(4) of Directive No 2001/83/EC)

Denosumab: supply and approvals

33 authorised products on the HPRA list contain Denosumab. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 21 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 21 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 21 Nov 2026)
Recent EMA authorisation
Denosumab Ascend, 28 Aug 2026 (biosimilar), Ascend GmbH
Osqay, 8 Jan 2026 (biosimilar), Theramex Ireland Limited

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 1890. It has been authorised for 1 year (since 12 February 2025). The HPRA list does not say whether it is on sale.

Open the European Commission’s Union Register record →

Other medicines with Denosumab in Ireland

32 other products on the HPRA list contain Denosumab, from 17 licence holders; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Acvybra 60 mg solution for injection in pre-filled syringeReddy Holding GmbHCentralised EU authorisationNot stated
BOMYNTRA 120 mg solution for injection in pre-filled syringeFresenius Kabi Deutschland GmbHCentralised EU authorisationNot stated
BOMYNTRA 120 mg solution for injection in vialFresenius Kabi Deutschland GmbHCentralised EU authorisationNot stated
Bildyos 60 mg solution for injectionSciencepharma Sp. z o.o.Centralised EU authorisationNot stated
Bildyos 60 mg solution for injection in pre-filled syringeSciencepharma Sp. z o.o.Centralised EU authorisationNot stated
Bilprevda 120 mg solution for injectionHenlius Europe GmbHCentralised EU authorisationNot stated
Conexxence 60 mg solution for injection in pre-filled syringeFresenius Kabi Deutschland GmbHCentralised EU authorisationNot stated
Degevma 120 mg solution for injectionTEVA GmbHCentralised EU authorisationNot stated
Denbrayce 120 mg solution for injectionMabxience Research, S.L.Centralised EU authorisationNot stated
Enwylma 120 mg solution for injectionZentiva k.s.Centralised EU authorisationNot stated
Evfraxy 60 mg solution for injection in pre-filled syringeBiosimilar Collaborations Ireland LimitedCentralised EU authorisationNot stated
Izamby 60 mg solution for injection in pre-filled syringeMabxience Research, S.L.Centralised EU authorisationNot stated

All 33 products with Denosumab →

The licence holder

Samsung Bioepis NL B.V. holds 20 products on the HPRA list, with 10 different active substances; 0 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.